An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care

Hossein Shooli, Habibollah Dadgar, Yì-Xiáng J Wáng, Manochehr Seyedi Vafaee, Saman Rassaei Kashuk, Reza Nemati, Esmail Jafari, Iraj Nabipour, Ali Gholamrezanezhad, Majid Assadi, Mykol Larvie


PET imaging using novel radiotracers show promises for tumor grading and molecular characterization through visualizing molecular and functional properties of the tumors. Application of PET tracers in brain neoplasm depends on both type of the neoplasm and the research or clinical significance required to be addressed. In clinical neuro-oncology, 18F-FDG is used mainly to differentiate tumor recurrence from radiation-induced necrosis, and novel PET agents show attractive imaging properties. Novel PET tracers can offer biologic information not visible via contrast-enhanced MRI or 18F-FDG PET. This review aims to provide an update on the complementary role of PET imaging in neuro-oncology both in research and clinical settings along with presenting interesting cases in this context.